– BELGIUM, Zwijnaarde – Sequana Medical NV (EBR: SEQUA), an innovator in the treatment of diuretic-resistant fluid overload in liver disease, malignant ascites, and heart failure, today announced the appointment of Jackie Fielding, former VP of Medtronic with more than 30 years of experience in the healthcare industry, to its Board as an Independent Non-Executive Director, effective immediately upon approval by the Board of Directors.
“We are delighted to welcome Jackie Fielding to our Board of Directors. Her extensive experience in the development and commercialisation of innovative medical devices and as a board member in both the corporate and public sectors will be invaluable as we progress the development of alfapump and alfapump DSR, seeking to transform the care of liver disease and heart failure,” said Board Chairman, Pierre Chauvineau.
Jackie Fielding replaces Jason Hannon who is stepping down from the Board of Directors.
Pierre Chauvineau commented: “We thank Jason for his tremendous contributions and wish him well with his return to California.”
About Jackie Fielding
Jackie Fielding spent 28 years with Medtronic, most recently as VP UK / Ireland, where she was responsible for more than 700 staff and revenue of approximately $750 million. She held several external posts alongside her role at Medtronic, including Chair of the BCIA and council member of the BCIS.
In 2010, she was elected to the Board of Directors of ABHI and in 2015 was appointed Vice-Chair. Ms. Fielding has worked with the UK’s NHS Clinical Entrepreneur program and was a member of the Ministerial Medical Technology Strategy Group. She is Non-Executive Director on the Boards of UK’s NICE (National Institute for Health and Care Excellence), 3D Life Prints, and Northumbria Primary Care, of which she is also Chair.
“I look forward to working with the Sequana Medical Board of Directors and Management Team,” said Jackie Fielding. “I believe that their alfapump and Direct Sodium Removal technologies have the potential to transform the care of diuretic-resistant fluid overload, and look forward to contributing my experience and knowledge to the success of the Company.”
About Sequana Medical
Sequana Medical is a commercial-stage medical device company utilizing its proprietary alfapump® and DSR® (Direct Sodium Removal) technologies to develop innovative treatments for fluid overload in liver disease, malignant ascites, and heart failure where diuretics are no longer effective. Fluid overload is a frequent complication of many large diseases including advanced liver disease driven by NASH (non-alcoholic steatohepatitis)-related cirrhosis and heart failure, with diuretic resistance being widespread. The U.S. market for the alfapump resulting from NASH-related cirrhosis is forecast to exceed €3 billion annually within the next 10-20 years. The heart failure market for DSR and the alfapump DSR® is estimated to be over €5 billion annually in the U.S. and EU5 by 2026.
The alfapump is a unique, fully implanted wireless device that automatically pumps fluid from the abdominal cavity into the bladder, where it is naturally eliminated through urination. DSR is Sequana Medical’s proprietary approach to managing sodium and fluid overload through the use of a sodium-free infusate administered into the abdominal cavity.
In the U.S., the Company’s key growth market, the alfapump has been granted breakthrough device designation by the FDA for recurrent or refractory ascites due to liver cirrhosis. Interim data from the ongoing North American pivotal study showed positive outcomes against all primary endpoints of the study and a rapid and persistent clinically important improvement in quality of life. This study is intended to support a future marketing application of the alfapump in the U.S. and Canada. In Europe, the alfapump is CE-marked for the management of refractory ascites due to liver cirrhosis and malignant ascites and is included in key clinical practice guidelines. Over 850 alfapump systems have been implanted to date.
Sequana Medical has combined its proven alfapump and proprietary DSR therapy and is developing the alfapump DSR, a breakthrough approach to fluid overload due to heart failure. RED DESERT, the repeated dose alfapump DSR study in diuretic-resistant heart failure patients has demonstrated that repeated DSR therapy can both manage the fluid and sodium balance of these patients as well as restore their diuretic response and improve their cardio-renal status. The SAHARA DESERT study of alfapump DSR in decompensated heart failure patients is ongoing.
For more information: https://www.sequanamedical.com
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.